The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Sickle Cell Disease Treatments-Global Market Insights and Sales Trends 2024
Synopsis
Sickle Cell Disease (SCD) is a group of blood disorders typically inherited from a person's parents.
The global Sickle Cell Disease Treatments market size is expected to reach US$ 602.6 million by 2029, growing at a CAGR of 5.1% from 2023 to 2029. The market is mainly driven by the significant applications of Sickle Cell Disease Treatments in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Clinics and Others, are propelling Sickle Cell Disease Treatments market. Infection Prevention with Vaccination and Antibiotics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Blood Transfusion segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sickle Cell Disease Treatments, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sickle Cell Disease Treatments market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sickle Cell Disease Treatments market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sickle Cell Disease Treatments sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sickle Cell Disease Treatments covered in this report include AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Novartis, Pfizer, Baxter, Emmaus Life Sciences, Bluebird Bio and Global Blood Therapeutics, etc.
The global Sickle Cell Disease Treatments market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Eli Lilly
Bristol-Myers Squibb
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird Bio
Global Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals
Global Sickle Cell Disease Treatments market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sickle Cell Disease Treatments market, Segment by Type:
Infection Prevention with Vaccination and Antibiotics
Blood Transfusion
The Medication Hydroxycarbamide
A Transplant of Bone Marrow Cells
Global Sickle Cell Disease Treatments market, by Application
Hospitals
Ambulatory Surgical Centers
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Sickle Cell Disease Treatments companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Sickle Cell Disease (SCD) is a group of blood disorders typically inherited from a person's parents.
The global Sickle Cell Disease Treatments market size is expected to reach US$ 602.6 million by 2029, growing at a CAGR of 5.1% from 2023 to 2029. The market is mainly driven by the significant applications of Sickle Cell Disease Treatments in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Clinics and Others, are propelling Sickle Cell Disease Treatments market. Infection Prevention with Vaccination and Antibiotics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Blood Transfusion segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sickle Cell Disease Treatments, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sickle Cell Disease Treatments market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sickle Cell Disease Treatments market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sickle Cell Disease Treatments sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sickle Cell Disease Treatments covered in this report include AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Novartis, Pfizer, Baxter, Emmaus Life Sciences, Bluebird Bio and Global Blood Therapeutics, etc.
The global Sickle Cell Disease Treatments market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Eli Lilly
Bristol-Myers Squibb
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird Bio
Global Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals
Global Sickle Cell Disease Treatments market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sickle Cell Disease Treatments market, Segment by Type:
Infection Prevention with Vaccination and Antibiotics
Blood Transfusion
The Medication Hydroxycarbamide
A Transplant of Bone Marrow Cells
Global Sickle Cell Disease Treatments market, by Application
Hospitals
Ambulatory Surgical Centers
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Sickle Cell Disease Treatments companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Sickle Cell Disease Treatments
1.1 Sickle Cell Disease Treatments Market Overview
1.1.1 Sickle Cell Disease Treatments Product Scope
1.1.2 Sickle Cell Disease Treatments Market Status and Outlook
1.2 Global Sickle Cell Disease Treatments Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Sickle Cell Disease Treatments Market Size by Region (2018-2029)
1.4 Global Sickle Cell Disease Treatments Historic Market Size by Region (2018-2023)
1.5 Global Sickle Cell Disease Treatments Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Sickle Cell Disease Treatments Market Size (2018-2029)
1.6.1 North America Sickle Cell Disease Treatments Market Size (2018-2029)
1.6.2 Europe Sickle Cell Disease Treatments Market Size (2018-2029)
1.6.3 Asia-Pacific Sickle Cell Disease Treatments Market Size (2018-2029)
1.6.4 Latin America Sickle Cell Disease Treatments Market Size (2018-2029)
1.6.5 Middle East & Africa Sickle Cell Disease Treatments Market Size (2018-2029)
2 Sickle Cell Disease Treatments Market by Type
2.1 Introduction
2.1.1 Infection Prevention with Vaccination and Antibiotics
2.1.2 Blood Transfusion
2.1.3 The Medication Hydroxycarbamide
2.1.4 A Transplant of Bone Marrow Cells
2.2 Global Sickle Cell Disease Treatments Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Sickle Cell Disease Treatments Historic Market Size by Type (2018-2023)
2.2.2 Global Sickle Cell Disease Treatments Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Sickle Cell Disease Treatments Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Sickle Cell Disease Treatments Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Sickle Cell Disease Treatments Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Sickle Cell Disease Treatments Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Sickle Cell Disease Treatments Revenue Breakdown by Type (2018-2029)
3 Sickle Cell Disease Treatments Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Clinics
3.1.4 Others
3.2 Global Sickle Cell Disease Treatments Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Sickle Cell Disease Treatments Historic Market Size by Application (2018-2023)
3.2.2 Global Sickle Cell Disease Treatments Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Sickle Cell Disease Treatments Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Sickle Cell Disease Treatments Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Sickle Cell Disease Treatments Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Sickle Cell Disease Treatments Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Sickle Cell Disease Treatments Revenue Breakdown by Application (2018-2029)
4 Sickle Cell Disease Treatments Competition Analysis by Players
4.1 Global Sickle Cell Disease Treatments Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Sickle Cell Disease Treatments as of 2022)
4.3 Date of Key Players Enter into Sickle Cell Disease Treatments Market
4.4 Global Top Players Sickle Cell Disease Treatments Headquarters and Area Served
4.5 Key Players Sickle Cell Disease Treatments Product Solution and Service
4.6 Competitive Status
4.6.1 Sickle Cell Disease Treatments Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Sickle Cell Disease Treatments Products, Services and Solutions
5.1.4 AstraZeneca Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Sickle Cell Disease Treatments Products, Services and Solutions
5.2.4 Eli Lilly Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Bristol-Myers Squibb
5.3.1 Bristol-Myers Squibb Profile
5.3.2 Bristol-Myers Squibb Main Business
5.3.3 Bristol-Myers Squibb Sickle Cell Disease Treatments Products, Services and Solutions
5.3.4 Bristol-Myers Squibb Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Sickle Cell Disease Treatments Products, Services and Solutions
5.4.4 Novartis Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Sickle Cell Disease Treatments Products, Services and Solutions
5.5.4 Pfizer Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Baxter
5.6.1 Baxter Profile
5.6.2 Baxter Main Business
5.6.3 Baxter Sickle Cell Disease Treatments Products, Services and Solutions
5.6.4 Baxter Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.6.5 Baxter Recent Developments
5.7 Emmaus Life Sciences
5.7.1 Emmaus Life Sciences Profile
5.7.2 Emmaus Life Sciences Main Business
5.7.3 Emmaus Life Sciences Sickle Cell Disease Treatments Products, Services and Solutions
5.7.4 Emmaus Life Sciences Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.7.5 Emmaus Life Sciences Recent Developments
5.8 Bluebird Bio
5.8.1 Bluebird Bio Profile
5.8.2 Bluebird Bio Main Business
5.8.3 Bluebird Bio Sickle Cell Disease Treatments Products, Services and Solutions
5.8.4 Bluebird Bio Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.8.5 Bluebird Bio Recent Developments
5.9 Global Blood Therapeutics
5.9.1 Global Blood Therapeutics Profile
5.9.2 Global Blood Therapeutics Main Business
5.9.3 Global Blood Therapeutics Sickle Cell Disease Treatments Products, Services and Solutions
5.9.4 Global Blood Therapeutics Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.9.5 Global Blood Therapeutics Recent Developments
5.10 Sangamo Therapeutics
5.10.1 Sangamo Therapeutics Profile
5.10.2 Sangamo Therapeutics Main Business
5.10.3 Sangamo Therapeutics Sickle Cell Disease Treatments Products, Services and Solutions
5.10.4 Sangamo Therapeutics Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.10.5 Sangamo Therapeutics Recent Developments
5.11 Acceleron Pharma
5.11.1 Acceleron Pharma Profile
5.11.2 Acceleron Pharma Main Business
5.11.3 Acceleron Pharma Sickle Cell Disease Treatments Products, Services and Solutions
5.11.4 Acceleron Pharma Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.11.5 Acceleron Pharma Recent Developments
5.12 Arena Pharmaceuticals
5.12.1 Arena Pharmaceuticals Profile
5.12.2 Arena Pharmaceuticals Main Business
5.12.3 Arena Pharmaceuticals Sickle Cell Disease Treatments Products, Services and Solutions
5.12.4 Arena Pharmaceuticals Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.12.5 Arena Pharmaceuticals Recent Developments
5.13 Alnylam Pharmaceuticals
5.13.1 Alnylam Pharmaceuticals Profile
5.13.2 Alnylam Pharmaceuticals Main Business
5.13.3 Alnylam Pharmaceuticals Sickle Cell Disease Treatments Products, Services and Solutions
5.13.4 Alnylam Pharmaceuticals Sickle Cell Disease Treatments Revenue (US$ Million) & (2018-2023)
5.13.5 Alnylam Pharmaceuticals Recent Developments
6 North America
6.1 North America Sickle Cell Disease Treatments Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Sickle Cell Disease Treatments Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Sickle Cell Disease Treatments Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Sickle Cell Disease Treatments Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Sickle Cell Disease Treatments Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Sickle Cell Disease Treatments Market Dynamics
11.1 Sickle Cell Disease Treatments Industry Trends
11.2 Sickle Cell Disease Treatments Market Drivers
11.3 Sickle Cell Disease Treatments Market Challenges
11.4 Sickle Cell Disease Treatments Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
